BRIEF-Adagene Announces First Patients Dosed In Global Phase 1 Clinical Trial Of Adg126, Lead Safebody™ Program

Reuters · 03/16/2021 12:57
BRIEF-Adagene Announces First Patients Dosed In Global Phase 1 Clinical Trial Of Adg126, Lead Safebody™ Program

- Adagene Inc ADAG.O:

  • ADAGENE ANNOUNCES FIRST PATIENTS DOSED IN GLOBAL PHASE 1 CLINICAL TRIAL OF ADG126, LEAD SAFEBODY™ PROGRAM

Source text for Eikon: ID:nGNX9tG41S

Further company coverage: ADAG.O


((Reuters.Briefs@thomsonreuters.com;))